This facility is part of the Institut Pasteur’s Center for Animal Resources and Research.

It produces mice harboring a human immune system (HIS mice) and provide expertise for the possible applications of this model.

HIS mice engrafted with human Hematopoietic stem cells (HSC) are advantageous in vivo models for long-term studies in the field of human immune cells biologyimmune-oncology and infectious disease. They constitute a small animal model in which to analyze potency and safety of new drugs modulating the immune system.

The Biomics Core Facility is the C2RT structure at Institut Pasteur for Next Generation Sequencing and includes both short and long-read technologies.

The Biomics Platform mission is to facilitate scientific discovery within Pasteur Institute’s network and academic research institutes. Biomics accepts both service and collaborative projects and works closely with the C3BI and DSI to provide data analysis solutions and data storage for researchers. Please contact us for pricing and turnaround times. Our website, https://biomics.pasteur.fr, allows you to:

Here are some examples of what we propose (Procaryotes, Eukaryotes and Viruses):

  1. Technology: Short-Reads (Illumina), Long-Reads (PacBio & Nanopore)
  2. DNA-Seq: Sequencing de novo and targeted
  3. RNA-Seq: Transcriptomic Analysis
  4. Metagenomic: Targeted sequencing studies (16S, 18S, ITS) or random (Shotgun)
  5. Genotyping (autonomous access)
  6. Bioinformatics: NGS data analysis (RNA-Seq, Variant, Assembly, others…)

Biomics and its staff of experts work hard for the successful and timely processing of all samples and requests.

The platform’s ambition is to develop serological or antigenic in vitro diagnostic test (IVD) as fast as possible, since 2020 for SARS-CoV-2, today for other viral, microbial or parasitic infectious agents, and tomorrow for global health applications on human, animal and environmental samples. The cross-disciplinary talents of our team weave together physics, chemistry, biology and engineering to imagine and design these diagnostic health tests of the future.

Mutualized Platform for Microbiology (P2M) is open to all the reference laboratories of the Institut Pasteur, in Paris and within the Pasteur Network, providing easy access to next generations multi-pathogenic sequencing (Illumina and Ion Torrent technologies).

The Platform was created in 2015 and has extensive experience of multipathogen sequencing.

Results can be downloadable remotly and sequence analysis can be carried out by the HUB bio info of the Institut Pasteur in Paris on request.

This platform is part of the Photonic BioImaging Unit of Technology and Service (UTechS) of the Institut Pasteur

The mission of the PFBMI is to provide an added value to a great variety of biological projects, enabling the characterization of the intrinsic properties of macromolecules and their assemblies (size, shape, folding, stability auto-association,…) and of the interactions in which they are involved (stoichiometry, thermodynamic and kinetic parameters, …). PFBMI equipments are available for the entire scientific community, in France and abroad, but a priority is given to teams from Institut Pasteur and the Institut Pasteur International Network.

Our core facility provides support in developing and characterizing VHH/nanobodies against the desired antigens. The main goal of this collaboration is to provide the right nanobodies that suit to the need of the user. We try not only to provide nanobodies but we can modify them: for example, according to the need, the nanobodies can be engineered to add a fluorochrome, to perform imaging; in this way, bispecific molecules can be created.

The CNCM is an International Depositary Authority (IDA) under the Budapest Treaty (BT). The CNCM receives deposits of accepts bacteria, filamentous fungi, yeasts, bacteriophages, viruses, animal, and human cell lines, for national and international patent procedures or other purposes requiring high secrecy requirements.
The provision of biological material preserved at the CNCM is governed by the BT implementing regulations.

The objective of the platform is to bridge biology and engineering in order to help the development of biomedical projects with a strong technological focus. Practically we provide the campus with essential technological bricks and expertise in microfluidics and biomaterials. We have developed in-house capabilities in the field of microfabrication, photo- and soft-lithography, advanced 3D cell culture systems, organoids and Organ-on-Chip technology especially targeted for the better understanding of complex cell-microenvironment interactions. In addition we also provide service based on standard organ-on-chip devices.